17 / 21
Page 47
December 06-07 , 2018
Amsterdam, Nether l ands
Journal of Neuropsychiatry
ISSN: 2471-8548
Alzheimer’s and Dementia 2018
1 3
t h
W o r l d c o n g r e s s o n
Alzheimer’s and Dementia
R
eceptol® oral spray was used in HIV positive patients as a model with CD4 counts of more than 100 cells/cmm and CD8 count
of more than 400 cells/cmm to determine its immunity boosting capacity based on large number of indications approved by
US and EU PTO (US Patent# 9,249,188) in 2016 including for Alzheimer’s and Dementia. Receptol® oral spray is assessed for its
efficacy in treatment of HIV in a study without anti-retroviral therapy/observed therapy-short course (ART) based on the reduction
in viral load and clinical symptoms as primary efficacy results. Absolute CD4/CD8 counts and various physical parameters
were evaluated as secondary efficacy results. Receptol active ingredient is Patented Radha108 nano peptides, isolated from
mammalian colostrum with vaccine like antiviral and immunomodulator activity via building body’s own immune system and
attachment inhibition on the cell surface receptors. The mode of action is based on Radha 108 crossing the blood brain barrier
and sending signals via pituitary to thymus and bone marrow to build body’s own immune system naturally strong via release
of cytokines, interleukins and interferon etc. creating paradigm shift in healthcare from prevention to cure which was exhibited
in this study. It cures all clinical and physical symptoms associated with AIDS and reduction in viral load and increase in CD4
absolute count with in a period of 3 months accelerated study conducted by Indian Council of Medical Research, Govt of India.
Similar effects were observed in observational study conducted on Alzheimer’s and dementia and other immunity disorders.
drpawan@biomix.in info@biomix.inAn interventional phase III accelerated study to
determine the efficacy and safety of RECEPTOL®
oral spray (Radha108 Nano peptides) used in HIV
positive patients with multiple symptoms as a
stand-alone mono therapy and that could be an
answer to Alzheimer’s and dementia and other
immunity disorders
Pawan Saharan
Biomix Network Inc., USA and India
J Neurol Neurosci 2018, Volume: 2
DOI: 10.21767/2471-8548-C1-003